% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Porcari:289450,
      author       = {S. Porcari and W. Fusco and I. Spivak and M. Fiorani and A.
                      Gasbarrini and E. Elinav$^*$ and G. Cammarota and G. Ianiro},
      title        = {{F}ine-tuning the gut ecosystem: the current landscape and
                      outlook of artificial microbiome therapeutics.},
      journal      = {The lancet / Gastroenterology $\&$ Hepatology},
      volume       = {9},
      number       = {5},
      issn         = {2468-1253},
      address      = {London},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2024-00772},
      pages        = {460 - 475},
      year         = {2024},
      abstract     = {The gut microbiome is acknowledged as a key determinant of
                      human health, and technological progress in the past two
                      decades has enabled the deciphering of its composition and
                      functions and its role in human disorders. Therefore,
                      manipulation of the gut microbiome has emerged as a
                      promising therapeutic option for communicable and
                      non-communicable disorders. Full exploitation of current
                      therapeutic microbiome modulators (including probiotics,
                      prebiotics, and faecal microbiota transplantation) is
                      hindered by several factors, including poor precision,
                      regulatory and safety issues, and the impossibility of
                      providing reproducible and targeted treatments. Artificial
                      microbiota therapeutics (which include a wide range of
                      products, such as microbiota consortia, bacteriophages,
                      bacterial metabolites, and engineered probiotics) have
                      appeared as an evolution of current microbiota modulators,
                      as they promise safe and reproducible effects, with variable
                      levels of precision via different pathways. We describe the
                      landscape of artificial microbiome therapeutics, from those
                      already on the market to those still in the pipeline, and
                      outline the major challenges for positioning these
                      therapeutics in clinical practice.},
      subtyp        = {Review Article},
      keywords     = {Humans / Microbiota / Probiotics: therapeutic use /
                      Prebiotics / Gastrointestinal Microbiome / Fecal Microbiota
                      Transplantation / Prebiotics (NLM Chemicals)},
      cin          = {F220 / D480},
      ddc          = {610},
      cid          = {I:(DE-He78)F220-20160331 / I:(DE-He78)D480-20160331},
      pnm          = {314 - Immunologie und Krebs (POF4-314)},
      pid          = {G:(DE-HGF)POF4-314},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:38604200},
      doi          = {10.1016/S2468-1253(23)00357-6},
      url          = {https://inrepo02.dkfz.de/record/289450},
}